Q-omics provides the consensus-scored HES3 profile across patient tissues and cancer cell-line models. HES3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, HES3 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, HES3 RNA expression shows 10,082 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, BRCA, and TGCT as cancer lineages where HES3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HES3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HES3 survival associations across molecular data types. HES3 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HES3 RNA expression–survival associations across cancer types. High HES3 expression shows unfavorable associations in LIHC, READ, THCA and DLBC, but favorable associations in LUAD and LAML. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for HES3 RNA expression.
This table summarizes HES3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HES3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HES3 shows lower tumor expression in COAD and higher tumor expression in BRCA. The BRCA box plot shows higher HES3 RNA expression in tumor versus normal tissue (log2 FC = +0.013, t-test p = .024).
This table shows molecular features associated with HES3 in patient tissues and cancer cell lines. In patient samples, HES3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HES3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
